acut
viral
infect
upper
respiratori
tract
also
refer
common
cold
frequent
observ
diseas
human
respiratori
viral
infect
lead
hospit
per
year
children
year
age
unit
state
consider
morbid
mortal
adult
infant
caus
respiratori
viral
infect
recent
review
morbid
caus
viral
upper
respiratori
tract
infect
urti
ensu
complic
pronounc
individu
preexist
respiratori
condit
asthma
numer
treatment
approach
claim
reduc
symptom
intervent
conclus
demonstr
display
antivir
activ
effect
decreas
durat
sever
manifest
recent
review
report
lack
efficaci
otc
overthecount
cough
cold
medicin
children
reveal
inabl
reduc
rate
sever
advers
event
substanc
diphenhydramin
codein
associ
signific
side
effect
children
thu
restrict
applic
sever
current
avail
therapi
recent
potent
antivir
effect
sever
respiratori
virus
demonstr
iotacarrageenan
polym
deriv
red
seawe
carrageenan
shown
display
antivir
activ
rang
anim
virus
test
clinic
prevent
sexual
transmit
viral
infect
iotacarrageenan
recent
shown
potent
inhibitor
papilloma
viru
invitro
even
concentr
carrageenan
use
food
addit
centuri
indigest
polysaccharid
extract
red
alga
seawe
ad
food
gell
agent
emulsifi
carrageenan
grant
gra
gener
recogn
safe
statu
unit
state
thu
document
safeti
substanc
carrageenan
increas
viscos
appli
nasal
spray
therebi
prolong
humidif
nasal
mucosa
addit
solut
form
barrier
direct
interact
carrageenan
virus
human
rhinovirus
trap
inactiv
polym
result
recent
pilot
studi
adult
patient
show
applic
nasal
spray
contain
iotacarrageenan
three
time
per
day
allevi
symptom
common
cold
reduc
viral
load
nasal
mucosa
herebi
efficaci
carrageenan
shown
local
symptom
wherea
system
symptom
remain
base
observ
present
studi
conduct
evalu
antivir
efficaci
nasal
spray
contain
iotacarrageenan
children
regard
allevi
symptom
sequela
common
cold
tss
use
base
evalu
eight
lead
clinic
featur
includ
system
symptom
headach
muscl
ach
chilli
system
symptom
score
sss
local
symptom
includ
sore
throat
block
nose
runni
nose
cough
sneez
local
symptom
score
lss
accord
publish
score
system
sever
rate
fourpoint
scale
zero
indic
absenc
symptom
score
repres
mild
moder
sever
symptom
respect
previous
healthi
immunocompet
children
adolesc
year
age
symptom
acut
rhiniti
prevail
less
hour
total
symptom
score
tss
enrol
studi
januari
januari
low
symptom
score
chosen
inclus
criterion
higher
tss
would
led
use
comed
potenti
bias
effect
carrageenan
immunocompet
evalu
clinic
includ
histori
less
bacteri
infect
per
year
without
stay
intens
care
unit
without
histori
chronic
diseas
urti
defin
presenc
appropri
symptom
accord
scale
describ
suspect
bacteri
infect
recent
use
antimicrobi
drug
intranas
treatment
first
present
exclus
criteria
howev
addit
medic
could
prescrib
case
fever
bacteri
otiti
wheez
persist
cough
pneumonia
upon
decis
physician
line
austrian
legal
requir
written
inform
consent
obtain
children
year
age
legal
guardian
instanc
enrol
studi
first
visit
medic
histori
record
physic
examin
perform
sampl
molecular
viru
test
obtain
standard
aspir
nasal
secret
sampl
frozen
store
use
patient
assign
receiv
nasal
spray
contain
either
iotacarrageenan
sodium
chlorid
placebo
sodium
chlorid
random
blind
manner
alloc
ratio
use
simpl
unrestrict
randomis
concentr
iotacarrageenan
sodium
chlorid
studi
medic
chosen
ident
compar
previous
perform
pilot
studi
use
optim
galen
composit
nasal
spray
contain
sequenti
number
random
alloc
sequenc
gener
independ
statistician
particip
enrol
studi
nurs
investig
pediatrician
assign
particip
intervent
children
andor
legal
guardian
receiv
standard
diari
record
symptom
addit
medic
singl
puff
ml
spray
per
nostril
administ
three
time
per
day
total
seven
day
patient
parent
request
record
symptom
permit
assess
tss
first
week
treatment
follow
two
week
day
record
presenc
absenc
symptom
request
determin
diseas
durat
followup
examin
patient
collect
nasal
secret
sampl
molecular
viru
test
perform
three
five
day
treatment
second
visit
final
examin
collect
symptom
diari
evalu
carri
third
visit
day
molecular
screen
quantit
assess
viral
load
perform
respiratori
virus
includ
rhinoviru
rv
respiratori
syncyti
viru
rsv
human
metapneumoviru
mpv
influenza
infa
viru
influenza
b
infb
viru
parainfluenzaviru
coronavirus
cov
method
describ
previous
detail
descript
viru
analysi
see
addit
file
studi
approv
local
irb
committe
name
ethikkommiss
st
anna
kinderspit
project
approv
number
line
austrian
legal
requir
written
inform
consent
obtain
children
year
age
legal
guardian
instanc
studi
perform
complianc
ich
note
guidanc
good
clinic
practic
principl
declar
helsinki
local
drug
regul
standard
oper
procedur
investig
sponsor
cro
involv
studi
protocol
attach
document
approv
respons
ethic
committe
comparison
verum
placebo
group
done
mean
utest
continu
variabl
mean
chi
squar
test
ordin
nomin
variabl
viral
load
compar
use
student
ttest
logarithm
transform
data
comparison
time
diseas
clearanc
log
rank
mantel
cox
test
use
calcul
requir
sampl
size
base
previou
result
obtain
adult
patient
indic
data
individu
would
suffici
obtain
signific
result
primari
endpoint
mean
tss
day
signific
level
percent
power
decid
recruit
least
patient
order
abl
analyz
itt
intent
treat
popul
least
patient
analysi
per
protocol
pp
patient
total
patient
clinic
confirm
acut
symptom
common
cold
assess
elig
within
one
year
studi
period
figur
patient
characterist
shown
tabl
main
reason
exclus
failur
return
studi
document
case
withdraw
consent
ultim
children
could
includ
itt
cohort
analyz
accordingli
major
children
test
posit
least
one
viru
mean
rang
visit
frequent
detect
viral
pathogen
human
rhinoviru
follow
coronaviru
influenza
viru
influenza
b
viru
human
metapneumaviru
parainfluenzaviru
respiratori
syncyti
viru
number
virus
detect
individu
patient
sampl
obtain
visit
one
two
group
display
figur
patient
itt
cohort
signific
differ
observ
verum
placebo
treatment
regard
primari
efficaci
variabl
mean
total
symptom
score
tss
day
studi
figur
addit
file
tabl
mean
tss
day
sd
iotacarrageenan
group
sd
placebo
group
predefin
secondari
endpoint
includ
tss
differ
studi
day
total
system
total
local
symptom
score
also
show
signific
differ
iotacarrageenan
placebo
group
figur
detail
symptomdiari
request
first
week
studi
day
presenc
absenc
common
cold
symptom
record
end
studi
period
day
significantli
higher
proport
patient
receiv
placebo
report
symptom
comparison
patient
group
treat
verum
p
moreov
mean
time
persist
symptom
allevi
report
patient
verumtr
group
significantli
shorter
comparison
placebo
group
versu
day
p
figur
post
hoc
analysi
patient
commonli
observ
viral
pathogen
includ
rhinoviru
n
coronaviru
n
reveal
similar
advantag
verumtr
group
figur
use
nasal
spray
well
toler
overal
frequenc
drugrel
advers
event
tend
lower
iotacarrageenan
group
compar
placebo
studi
period
advers
event
relat
upper
respiratori
tract
common
treatmentunrel
sever
advers
event
sae
observ
four
patient
includ
two
iotacarrageenan
group
two
placebo
group
secondari
object
studi
investig
effect
iotacarrageenan
nasal
spray
viru
elimin
nasal
fluid
sampl
incid
virus
observ
typic
common
cold
figur
topic
applic
iotacarrageenan
spray
reduc
viral
load
nasal
secret
significantli
higher
degre
placebo
day
treatment
p
figur
document
reduct
number
virus
visit
significantli
greater
verum
group
antivir
efficaci
iotacarrageenan
support
fact
patient
verum
group
less
placebo
group
test
virusneg
second
visit
addit
file
figur
observ
decreas
virusposit
patient
visit
statist
signific
verum
group
p
versu
p
second
visit
mean
number
virus
detect
iotacarrageenan
group
reduc
p
placebo
group
observ
reduct
signific
moreov
verum
patient
placebo
patient
clear
virus
second
visit
p
visit
incid
newli
acquir
infect
virus
detect
visit
significantli
lower
verum
group
versu
p
patient
receiv
least
one
addit
drug
compat
studi
protocol
concomit
medic
includ
nonsteroid
antiinflammatori
agent
antituss
antibiot
other
addit
file
figur
address
notion
less
comed
could
permit
better
appreci
effect
iotacarrageenan
post
hoc
analysi
conduct
subgroup
patient
n
receiv
either
comed
n
one
addit
drug
n
patient
receiv
verum
show
trend
toward
lower
tss
compar
placebotr
patient
addit
file
figur
need
therapeut
strategi
urti
children
highlight
result
random
studi
use
otc
prepar
treatment
common
cold
children
year
age
reveal
signific
differ
verum
placebo
due
insuffici
data
applic
nasal
decongest
common
cold
children
use
recommend
patient
year
age
upper
respiratori
tract
infect
earli
childhood
contribut
signific
morbid
result
respiratori
complic
even
immunocompet
individu
date
causal
therapi
avail
instanc
urti
caus
predominantli
viral
pathogen
effect
therapeut
agent
avail
result
present
studi
show
signific
differ
iotacarrageenan
placebo
group
predefin
primari
endpoint
mean
tss
studi
day
may
due
low
tss
level
inclus
necessari
avoid
bia
higher
use
comed
furthermor
concentr
iotacarrageenan
use
previou
pilot
studi
adult
may
also
influenc
symptom
score
children
studi
group
receiv
one
comed
verum
group
predominantli
antiinflammatori
agent
antituss
less
frequent
antibiot
prescrib
conceiv
system
local
symptom
score
respect
affect
antipyret
antituss
medic
henc
neg
effect
unusu
high
preval
patient
multipl
comed
may
mask
effect
studi
medic
age
patient
studi
rang
one
year
mean
five
year
young
children
often
difficult
evalu
symptom
like
headach
muscl
ach
chilli
difficulti
evalu
symptom
children
recent
discuss
taylor
et
al
requir
care
consider
futur
studi
pediatr
patient
cohort
howev
mean
differ
time
complet
symptom
allevi
verum
placebo
group
day
report
effect
neuraminidas
inhibitor
treatment
influenza
adult
show
overal
benefit
placebo
treatment
approxim
one
day
anoth
secondari
object
studi
determin
viral
pathogen
intranas
viral
load
recent
data
demonstr
specif
viral
infect
coinfect
well
viral
load
contribut
diseas
sever
children
respiratori
infect
virus
detect
studi
similar
earlier
report
reveal
constel
associ
particularli
high
risk
complic
significantli
children
verum
group
test
virusneg
visit
fewer
children
display
multipl
virus
reveal
new
viral
infect
time
find
may
import
implic
recurr
viral
episod
prolong
reactiv
bronchial
inflamm
frequent
encount
complic
urti
regard
topic
effect
iotacarrageenan
could
instrument
reduc
incid
subsequ
lower
respiratori
tract
involv
major
limit
studi
includ
restrict
perform
two
nasal
aspir
newli
acquir
viral
infect
day
could
occur
placebo
group
follow
period
potenti
chang
proport
patient
symptom
second
limit
may
given
tss
questionnair
may
appropri
studi
popul
mean
age
year
despit
fact
viral
load
nasal
secret
reduc
iotacarrageenan
signific
allevi
symptom
children
common
cold
could
observ
prospect
random
placebocontrol
pediatr
studi
fund
marinom
biotechnologi
gmbh
logist
viru
sampl
laboratori
author
tl
mr
mv
work
author
declar
conflict
interest
financi
person
relationship
peopl
organis
could
inappropri
influenc
work
concept
design
studi
contribut
tf
az
data
analysi
interpret
perform
pe
np
mr
mv
draft
manuscript
import
intellectu
content
made
hw
gv
gf
cd
hg
tl
author
read
approv
final
manuscript
adult
nasal
spray
carrageenan
significantli
reduc
symptom
common
cold
first
pediatr
studi
carrageenan
significantli
reduc
viral
load
cytokin
level
nasal
mucosa
children
author
acknowledg
marinom
biotechnologi
gmbh
vienna
austria
provid
financi
support
studi
grant
number
funder
support
part
logist
sponsor
influenc
studi
design
collect
analysi
interpret
data
prepubl
histori
paper
access
http
